The most significant difference between 177Lu-PSMA-NARI-56 and 177Lu-PSMA-617 was observed on day 90, where the 177Lu-PSMA-NARI-56 group showed a 90% survival rate and 70% complete tumor regression, compared to only 30% survival in the 177Lu-PSMA-617 group. This evidence concerns the gene FOLH1 and neoplasm.